{
    "root": "35ce69c2-247e-02e8-e063-6294a90aa89f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Anastrozole",
    "value": "20250523",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "POLYETHYLENE GLYCOL 300",
            "code": "5655G9Y8AQ"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ANASTROZOLE",
            "code": "2Z07MYW1AZ"
        }
    ],
    "indications": "anastrozole aromatase inhibitor indicated : adjuvant treatment postmenopausal women hormone receptor-positive early breast cancer ( 1.1 ) first-line treatment postmenopausal women hormone receptor-positive hormone receptor unknown locally advanced metastatic breast cancer ( 1.2 ) treatment advanced breast cancer postmenopausal women disease progression following tamoxifen therapy . patients er-negative disease patients respond previous tamoxifen therapy rarely responded anastrozole ( 1.3 )",
    "contraindications": "one 1 mg tablet taken daily ( 2.1 )",
    "warningsAndPrecautions": "anastrozole tablets , usp 1 mg white off-white , round biconvex , film coated tablets , “ ahi ” debossing one side plain side supplied follows : bottles 30 tablets child-resistant closure ( ndc 16729-035-10 ) bottles 90 tablets child-resistant closure ( ndc 16729-035-15 ) bottles 500 tablets ( ndc 16729-035-16 ) bottles 1000 tablets ( ndc 16729-035-17 ) storage store controlled room temperature , 20 25°c ( 68 77°f ) [ usp ] . preserve tight container .",
    "adverseReactions": "hypersensitivity anastrozole contraindicated patient shown hypersensitivity reaction excipients . observed include anaphylaxis , angioedema , urticaria [ ( 6.2 ) ] .",
    "indications_original": "Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 )",
    "contraindications_original": "One 1 mg tablet taken once daily ( 2.1 )",
    "warningsAndPrecautions_original": "Anastrozole tablets, USP 1 mg are white to off-white, round biconvex, film coated tablets, with “AHI” debossing on one side and plain on other side and are supplied as follows:\n                  Bottles of 30 tablets with a child-resistant closure (NDC 16729-035-10)\n                  Bottles of 90 tablets with a child-resistant closure (NDC 16729-035-15)\n                  Bottles of 500 tablets (NDC 16729-035-16)\n                  Bottles of 1000 tablets (NDC 16729-035-17)\n                  \n                     Storage\n                  \n                  Store at controlled room temperature, 20 to 25°C (68 to 77°F) [see USP]. Preserve in tight container.",
    "adverseReactions_original": "Hypersensitivity\n                  \n                  Anastrozole is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. Observed reactions include anaphylaxis, angioedema, and urticaria\n \n  [see Adverse Reactions (\n  \n   6.2)]."
}